Clinical trials recruiting in Zion, Illinois

Phase breakdown

Conditions recruiting in Zion, Illinois

Recruiting trials in Zion, Illinois

• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
  NCT06427941 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
  NCT06790693 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
  NCT07365241 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
  NCT07100106 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  NCT07144280 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
  NCT07007559 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
  NCT04852887 · Phase: Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female)
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
  NCT05080673 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 70 Years · Sex: All (male and female)
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
  NCT07288034 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
  NCT06216301 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
  NCT03851445 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
  NCT07125729 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
  NCT07595874 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
  NCT05232916 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
  NCT07291037 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
  NCT05827081 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
  NCT07594106 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
  NCT05732831 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
  NCT07531095 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
  NCT05564377 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female)
• Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
  NCT07200830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
  NCT03191149 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
  NCT05624996 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Zion, Illinois?

30 recruiting trials have at least one study site in Zion, Illinois.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.